Navigation Links
Catalyst Biosciences Announces Agreement With MedImmune to Discover and Develop Engineered Protease Therapeutics
Date:7/7/2009

SOUTH SAN FRANCISCO, Calif., July 7 /PRNewswire/ -- Catalyst Biosciences, Inc. today announced the signing of an exclusive worldwide research and license agreement with MedImmune, the global biologics unit of AstraZeneca plc, to develop novel engineered proteases that specifically degrade or modulate two targets, one of which will address inflammatory and autoimmune diseases.

Catalyst will receive undisclosed upfront licensing fees, full-time employee (FTE) support and milestone payments totaling up to $195 million, exclusive of royalty payments, for the development of drug candidates against two distinct targets.

Through the collaboration, MedImmune will support the discovery research and preclinical development by Catalyst of Alterase(TM) therapeutics against an undisclosed target, with an option to expand the agreement to include a second target. Alterase therapeutics are next-generation, protease biologics engineered with the ability to catalytically cleave and inactivate disease-causing proteins. MedImmune will be responsible for all development, manufacturing, and commercialization efforts associated with the products discovered through the collaboration in exchange for future milestones and royalties.

"We are very pleased to add MedImmune, a leading developer of biologic therapies, as a partner," said Nassim Usman, Ph.D., Chief Executive Officer of Catalyst Biosciences. "Our Alterase drug discovery engine is creating novel next-generation protein therapeutics against a broad variety of important disease targets. Collaborations such as this demonstrate the high value of our discovery and protein engineering capabilities."

About MedImmune

MedImmune, the worldwide biologics business for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately 3,100 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline of promising candidates, we aim to be the next revolutionary force in biotechnology by delivering life-changing products, industry-leading performance, and a tireless commitment to improving patient health. For more information, visit MedImmune's website at www.medimmune.com.

About Catalyst Biosciences

Catalyst Biosciences is developing the next generation of biopharmaceuticals by harnessing the catalytic power of engineered proteases to target proteins underlying disease. Catalyst's discovery platform rapidly creates and optimizes tailor-made protease drug candidates that cleave a wide variety of disease targets, either by improving existing protease drugs or by creating new protease drugs, known as Alterase(TM) therapeutics. Initially, Catalyst is focusing its product development efforts on drug candidates for hemophilia, age-related macular degeneration and inflammation. To date, Catalyst has established research, development and license agreements with Wyeth Pharmaceuticals, Centocor Research & Development, Inc. and MedImmune LLC. Catalyst is privately-held with backing by leading venture firms including Burrill & Company, Essex Woodlands Health Ventures, HealthCare Ventures, Johnson & Johnson Development Corporation, Morgenthaler Ventures, Novartis BioVentures, RCT BioVentures and Sofinnova Ventures. For more information, please visit www.catbio.com.

    Catalyst Biosciences, Inc.
    Erik Wiberg
    +1.650.266.8654
    ewiberg@catbio.com

    BCC Partners for Catalyst Biosciences, Inc.
    Karen L. Bergman or Michelle Corral
    +1.650.575.1509 or +1.415.794.8662


'/>"/>
SOURCE Catalyst Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
2. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
3. Catalyst Pharmaceutical Partners Reports Third Quarter 2007 Financial Results
4. Catalyst Pharmaceutical Partners Announces Positive Phase II Trial Results for Vigabatrin in the Treatment of Cocaine Addiction
5. CATalyst Summit Declared a Success: Its All About the Cat!
6. Cardiva Medical, Inc. to Present Highlights of the Boomerang Catalyst(TM) II System at the Investment in Innovation (In3) West Conference on February 29, 2008 in Las Vegas, NV
7. Catalyst Pharmaceutical Partners, Inc. Names Director - Corporate Clinical Compliance
8. Case in Point: Patient Control of Data Critical Catalyst for Online Health Care Revolution
9. Catalyst Pharmaceutical Partners, Inc. Set to Join Russell Microcap(R) Index
10. Congress Approves ePrescribing Initiative in Medicare Reform Bill: Critical Catalyst in Driving a New Generation of Prescribing
11. CATalyst Council Forms to Address Feline Health Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... ... ... Mother’s Day is mixed with worry and fear for new mothers those whose babies are ... first time ever, the March of Dimes and Random Acts of Flowers ... crib surrounded by lifesaving equipment or peering through a glass window at a baby they ...
(Date:5/6/2016)... ... May 06, 2016 , ... ... Service, their latest implementation service offering for global clients of Coupa ( Coupa ... , Bluvault’s Integration Service is a key component in the suite of ...
(Date:5/6/2016)... ... 06, 2016 , ... Online HR/benefits platforms offer a range of benefits functions ... brokers and health plans. “ The Rapid Emergence of Online Benefits Firms: Strategies for ... Inc. (AIS), will offer an accurate picture of online benefits today, and the possible ...
(Date:5/6/2016)... (PRWEB) , ... May 06, 2016 , ... The International ... Resort on the north end of the island close to the town famous for ... August 10th 2016. , “We continue to have an amazing experience in Greece, ...
(Date:5/6/2016)... ... May 06, 2016 , ... Few events ... made headlines mostly for its cost despite its potential to wipe out a ... the drug—part of a class called direct-acting antivirals (DAAs)—have created fallout in the ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... DUBLIN, May 5, 2016 , First ... and revenues of $964 million , First ... of $0.40 , Company revises 2016 financial ... to $4.03 billion and 2016 adjusted diluted non-GAAP earnings per ... Company provides updates regarding Generics business and manufacturing facility ...
(Date:5/5/2016)... 2016 Research and Markets has announced the ... 5 EU Markets"  report to their offering.  ,     (Logo: ... on the current Positron Emission Tomography (PET) scanner and cyclotron ... which includes France , Germany ... and the United Kingdom . ...
(Date:5/5/2016)... May 5, 2016 ... the  "Europe Systemic Lupus Erythematosus Market and ... their offering.       (Logo: ... research Europe Systemic Lupus Erythematosus Market and ... insights into Systemic Lupus Erythematosus pipeline products, ...
Breaking Medicine Technology: